MOTS-c Benefits: What Mouse and Human Studies Show

MOTS-c is a small peptide made by mitochondria. Here is what cell, mouse and human studies show about its benefits, its safety record and its regulatory status.

Signal IQ Editorial6 min read · Updated Nov 8, 2026
MOTS-c Benefits: What Mouse and Human Studies Show
In this article
  1. Where MOTS-c comes from
  2. The proposed mechanism
  3. What the evidence looks like at each level
  4. Safety picture
  5. Regulatory status
  6. Questions to bring to a clinician
  7. Frequently asked questions
  8. References

Mitochondria make a short peptide called MOTS-c, and cells appear to use it as a signal about energy status. Rodent experiments link it to leaner bodies on a high-fat diet, steadier insulin response and better stamina. Nobody has yet shown those effects in people who receive it, and it has no FDA approval.

Key takeaways
  • MOTS-c is built from a sequence hidden in mitochondrial DNA, not from the nuclear genome that encodes most proteins.
  • Almost every claimed benefit traces back to laboratory cells and mice.
  • In humans, researchers have measured the body’s own MOTS-c rising with exercise, which is a different question from whether giving it helps.
  • A placebo-controlled trial in prediabetes is under way; until it reports, the safety record in people is sparse.

Where MOTS-c comes from

Most proteins are written in the nucleus. A handful are written in the small circular genome inside mitochondria, and MOTS-c is one of them. A group at the University of Southern California reported it in Cell Metabolism in 2015 after spotting a short reading frame tucked inside the gene for 12S ribosomal RNA. The full name, “mitochondrial open reading frame of the 12S rRNA type-c”, simply records that location.

The peptide is only 16 amino acids long and can leave the cell, so it can circulate in blood. It sits in a small family of mitochondrial-derived peptides alongside humanin, a family that hints at mitochondria acting as signaling organelles rather than just power plants.

FeatureDetail
Genetic source12S rRNA gene in mitochondrial DNA
Length16 amino acids
Tissue most affected in early workSkeletal muscle
Proposed pathwayReduced folate-cycle and purine output, leading to AMPK activation

The proposed mechanism

In the discovery experiments, skeletal muscle looked like the main place MOTS-c acts. Inside cells it dampened the folate cycle and the purine production that depends on it. That shortfall switches on AMPK, an enzyme that registers low energy and pushes the cell to use fuel.

Exercise also engages AMPK, and that overlap is why headlines describe MOTS-c as imitating a workout. Treat that phrase as a working idea only. Giving MOTS-c to people has not been shown to reproduce what training does.

What the evidence looks like at each level

Laboratory and mouse studies

This is where the results are strongest and most consistent. Treated mice were protected from insulin resistance linked to age or a fatty diet, and from weight gain on that diet. A follow-up paper in Nature Communications in 2021, from the same laboratory, found better running and strength measures across young, middle-aged and elderly mice. Starting late in life still improved capacity. Two of its authors disclosed financial links to a company developing a MOTS-c analog, so independent replication matters.

Human observation

The 2021 paper also looked at people and found that muscle tissue and blood contain more native MOTS-c after exercise. That tells us the body makes the peptide in response to activity, not that an external supply is useful. A 2026 systematic review of exercise and mitochondrial-derived peptides could find just nine suitable studies. Most reported an increase after exercise, and the reviewers described the human literature as limited.

Human trials

  • CB4211 (NCT03998514): a randomized, placebo-controlled phase 1a/1b study of a MOTS-c analog, run with 88 volunteers who were healthy or had fatty liver disease. It looked at safety, tolerability and drug levels, finished in 2021, and has no results posted on ClinicalTrials.gov.
  • MOTS-c itself (NCT07505745): a quadruple-blind, placebo-controlled phase 2a trial testing 12 weeks of the peptide for insulin sensitivity in adults with prediabetes and overweight or obesity. It aims for 120 participants and lists February 2027 as the estimated primary completion. There are no results yet.

Claims about fat loss, endurance, glucose control or slower aging therefore rest on animal work. A 2026 review of peptides marketed to athletes drew the same line: results in animals exist, while strong human safety data do not.

Evidence tierWhere MOTS-c stands
Cell studiesFolate cycle, purine synthesis and AMPK effects
MiceLess diet-induced obesity and insulin resistance; better capacity
Human observationNatural levels rise with exercise; few studies
Analog trialSafety study done, results not posted
MOTS-c trialPhase 2a in prediabetes, recruiting
Approved medicineNone

Safety picture

No dependable list of side effects exists for people, because the trial that will record them systematically has not finished.

  • Regulator view: while MOTS-c was on FDA’s list of substances with significant compounding risk, the agency pointed to possible immune reactions and said it had found no human exposure data for finished products.
  • Policy view: an HHS policy document took the opposite tone, arguing that rodent studies and the analog trial showed no serious toxicity. The analog results have not been made public on the trial registry.
  • Product quality: vials sold as research-use-only are not made or inspected for human use, so purity is unknown without independent testing. See how to read a peptide CoA.

The source material cited no human pharmacokinetic study of MOTS-c, so half-life numbers circulating online most likely come from animals or analogs.

Regulatory status

No MOTS-c medicine is approved. Its compounding standing has changed repeatedly: FDA put it on a safety-risk list in 2023, took it off in 2026 once the nominations were withdrawn, and an interim HHS enforcement-discretion policy published on October 30, 2026 then named it among a few peptides pharmacies may compound for individual prescriptions under tight conditions. Discretion is not approval, and formal FDA rulemaking is still pending.

Note: Much MOTS-c on the market is labeled research-use-only and is not intended for human use. Any decision about a prescribed or compounded product should involve a qualified clinician. Research protocol ranges are on the Signal IQ MOTS-c page.

Questions to bring to a clinician

  • What does human evidence say about my particular goal, and does an approved option have stronger data?
  • Is the product a compounded drug, a trial material, or a research chemical?
  • Can I see the lot’s certificate of analysis?
  • Which measurements would show whether it does anything?

For related mitochondrial and metabolic compounds, see the Signal Library, the SS-31 page and peptides by goal. The regulatory divide is explained in research use vs human use, the Bloodwork Panel Planner helps organize labs, and Pulse can answer follow-ups. For a comparison with a drug class that does have approvals, read how retatrutide works.

Frequently asked questions

What is MOTS-c?

A short mitochondrial peptide first described in 2015, thought to influence muscle energy metabolism through AMPK.

What are the benefits of MOTS-c?

Mouse studies report protection from diet-induced obesity and insulin resistance and improved stamina. In people, only a rise in natural levels after exercise has been documented, not a benefit from supplying it.

Is MOTS-c FDA-approved?

No. A limited interim compounding policy exists, but it is enforcement discretion rather than approval.

What are the side effects of MOTS-c?

They are not established. FDA has raised possible immune reactions and the absence of human exposure data.

Is there a human trial of MOTS-c?

Yes, NCT07505745, a phase 2a placebo-controlled study in prediabetes. An earlier phase 1 study used the analog CB4211.

What is the half-life of MOTS-c?

No human pharmacokinetic study of MOTS-c itself was identified; figures online usually come from animals or analogs.

References

  1. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance, Cell Metabolism, 2015 — pubmed.ncbi.nlm.nih.gov
  2. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis, Nature Communications, 2021 — pubmed.ncbi.nlm.nih.gov
  3. Ayubi N et al. Mitochondrial-derived peptides activated by physical exercise: a systematic review, 2026 — pubmed.ncbi.nlm.nih.gov
  4. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, Sports Medicine, 2026 — pubmed.ncbi.nlm.nih.gov
  5. ClinicalTrials.gov NCT07505745 — clinicaltrials.gov
  6. ClinicalTrials.gov NCT03998514 — clinicaltrials.gov

Go deeper on Signal IQ

Dosing & protocolMOTS-CResearch profileMOTS-c

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading